Introduction
2 and phenylmethyl or 1-naphthylmethyl groups at position 6 were also prepared. In the second case, we synthesized novel DABOs featuring various C-6 monosubstituted phenylmethyl (such as CH 3 , OCH 3 , CF 3 or NH 2 groups, compounds 5a-l) or heteroarylmethyl (both mono and bicyclic) moieties (compounds of formula 6).
Materials and Methods: Chemistry
Melting points were determined on a Büchi 530 apparatus and are uncorrected. Infra-red (IR) spectra (KBr pellets) were recorded on a Perkin-Elmer 297 instrument.
1 H NMR spectra were recorded at 200 MHz on a Brüker AC 200 spectrometer. Chemical shifts are reported in δ (ppm) units with tetramethylsilane (Me 4 Si) as internal reference. All compounds were routinely checked by thin layer chromatography (TLC) and 1 H NMR. NMR data were consistent with the designed structures. TLC was performed on aluminum-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 F 254 ). Developed plates were visualized by UV light. Chromatographic purifications were performed on Merck silica gel 60. Solvents were reagent grade and, when necessary, were purified and dried by standards methods. Concentration of solutions after reactions and extractions involved the use of a rotary evaporator operating at a reduced pressure of approximately 20 Torr. Organic solu- (Tables 1 and 2 ) and biological studies (Tables 3  and 4) were dried in high vacuum over P 2 O 5 for 20 h at temperatures ranging from 25 to 90°C, depending on the melting point of the sample considered.
General procedure for the synthesis of ethyl 2-alkyl-4-aryl-3-oxobutyrate derivatives (7a-i,k,l,n-p,s-w,y,a′-c′). Procedure A. For example, Ethyl 2-n-butyl-4-phenyl-3-oxobutyrate (7n)
A solution of potassium hydroxide pellets (1.5 g, 26.6 mmol) in absolute ethanol (30 ml) was added to diethyl 2-n-butylmalonate (5.7 g, 5.8 ml, 26.6 mmol) at room temperature during a period of 1 h. The mixture was stirred overnight, and then concentrated under vacuum to remove ethanol. The residue was suspended in dry acetonitrile (100 ml) and, after stirring for 15 min, triethylamine (4.1 g, 5.6 ml, 40.5 mmol) and magnesium chloride (3.0 g, 31.6 mmol) were added, and stirring was continued at room temperature for 2 h. A solution of phenylacetyl imidazolide [prepared from phenylacetic acid (1.7 g, 12.6 mmol) and N,N-carbonyldiimidazole (CDI, 2.5 g, 15.2 mmol)] in acetonitrile (50 ml) was added and the reaction mixture was stirred overnight at room temperature. 13% HCl (150 ml) was cautiously added while keeping the temperature below 25°C and the resulting clear mixture was stirred for a further 15 min. The organic layer was separated from aqueous mixture, concentrated, and the residue dissolved in ethyl acetate (100 ml). The aqueous mixture was extracted twice with ethyl acetate (50 ml). The organic extracts were collected, washed with brine (100 ml), dried and evaporated to give 7n as an oil homogeneous on TLC analysis (SiO 2 /CHCl 3 ).
1 H NMR (CDCl 3 ) δ 0. General procedure for the synthesis of ethyl 4-(1H-pyrrol-1-yl)-and 4-(1H-indol-1-yl)-3-oxobutyrates (7x,z). Procedure B. For example, Ethyl 4-(1H-indol-1-yl)-3-oxobutyrate (7z)
A stirred suspension of sodium hydride (42.7 mmol, 1.9 g of 60% dispersion in mineral oil) in freshly distilled dimethoxyethane (80 ml) was cooled to -30°C. After 10 min, a solution of ethyl 4-chloroacetoacetate (5.8 ml, 42.7 mmol) in the same solvent (40 ml) was added dropwise and stirring was continued for 30 min. Then, a suspension of indole potassium salt [prepared 2 h before by reaction between indole (5.0 g, 42.7 mmol) and a mixture of finely crushed KOH (9.6 g, 170.7 mmol)] in dimethyl sulphoxide (85 ml) was added to the resulting mixture. After stirring at reflux overnight, the mixture was treated with 1N HCl (150 ml), extracted with ethyl acetate (3×70 ml) and dried. Removal of solvent gave a residue, which was purified by column chromatography (silica gel/ethyl acetate:n-hexane 1:10). General procedure for the synthesis of ethyl 2-ethyl-and 2-(1-methylethyl)-4-aryl-3-oxobutyrates (7j,m,q,r). Procedure C. For example, Ethyl 4-(2,6-difluorophenyl)-2-ethyl-3-oxobutyrate (7q)
A suspension of activated zinc dust (4.2 g, 64.1 mmol) in refluxing dry tetrahydrofuran (40 ml) under nitrogen atmosphere was treated with 4-5 drops of ethyl 2-bromobutyrate and stirred at room temperature for 1 h. Then 2,6-difluorophenylacetonitrile (2.0 g, 13.6 mmol) was added in one portion followed by addition of ethyl 2-bromobutyrate (6.6 g, 34.0 mmol) drop by drop during 1 h. The resulting mixture was stirred at reflux under nitrogen for 30 min, then was diluted with 100 ml of tetrahydrofuran and quenched with 50% aqueous potassium carbonate (15 ml). After stirring for 30 min the organic layer was separated, evaporated and the residue was dissolved in ethyl acetate (200 ml); the aqueous phase was extracted with ethyl acetate (2×50 ml), and the combined organic extracts were treated with 13 ml of 13% HCl and stirred at room temperature for 45 min. The organic layer was separated, washed with saturated aqueous sodium hydrogen carbon- General procedure for the synthesis of 5-alkyl-6-arylmethyl-3,4-dihydro-2-thioxopyrimidin-4(3H)-ones (8a-c′). Procedure D. For example, 3,4-Dihydro-6-phenylmethyl-5-(2-propenyl)-2-thioxopyrimidin-4(3H)-one (8k) Sodium metal (0.43 g, 0.019 g-atom) was dissolved in 30 ml of absolute ethanol, then thiourea (1.0 g, 13.0 mmol) and 7k (2.3 g, 9.3 mmol) were added to the clear solution. The mixture was heated at reflux for 5 h. After cooling, the solvent was removed, the residue was dissolved in water (50 ml) and the aqueous solution was made acid with 2N HCl. Solid precipitates were separated, filtered, washed with diethyl ether and dried in vacuo at 50°C for 6 h, whereas oily derivatives were extracted with ethyl acetate (3×50 ml), and the combined organic extracts were washed with brine (100 ml), dried and evaporated to dryness to give solid residues which were purified by crystallization.
1 H NMR (CDCl 3 ) δ 3. General procedure for the synthesis of 5-alkyl-2-alkylthio-3,4-dihydro-6-(hetero)arylmethylpyrimidin-4(3H)-ones (5a-h,k-z and 6a-w). Procedure E. For example, 3,4-Dihydro-2-(1-methylpropylthio)-6-(3-thianaphthenylmethyl)pyrimi din-4(3H)-one (6s) A mixture of 3,4-dihydro-6-(thianaphthen-3-ylmethyl)-2-thioxopyrimidin-4(3H)-one 8b′ (0.5 g, 1.8 mmol), 2-iodobutane (0.3 g, 0.2 ml, 1.8 mmol) and potassium carbonate (0.3 g, 1.8 mmol) in 2 ml of anhydrous N,Ndimethylformamide was stirred at room temperature for 8 h. The reaction mixture was poured on cold water (100 ml) and extracted with ethyl acetate (3×50 ml). The organic layers were collected, washed with brine (3×50 ml), dried and evaporated to furnish crude 6s as a solid, which was purified by column chromatography on silica gel (eluent: nhexane/ethyl acetate/methanol 12/3/1) followed by crystallization.
1 H NMR (CDCl 3 ) δ 0. Following this procedure 6-arylmethyl-2-cyclohexylthio-3,4-dihydropyrimidin-4(3H)-ones 6c,f,i,l,u were prepared by heating the reaction mixture at 80°C for 8 h. General procedure for the synthesis of 6-(2-aminophenylmethyl or 4-aminophenylmethyl)-3,4-dihydro-2-(1-methylpropylthio)pyrimidin-4(3H)-ones (5i,j). For example, 6-(4-aminophenylmethyl)-3,4-dihydro-2-(1-methylpropylthio) pyrimidin-4(3H)-one (5j) A solution of 3,4-dihydro-2-(1-methylpropylthio)-6-(4-nitrophenylmethyl)pyrimidin-4(3H)-one (0.94 g, 3.6 mmol) in ethanol (40 ml) was added dropwise to a solution of stannous chloride bihydrate (2.8 g, 12.5 mmol) in 37% HCl (13 ml). After heating at 90°C for 10 min, the reaction was diluted with water (100 ml) and made basic with sodium hydrogencarbonate saturated solution. The product was extracted with chloroform (3×50 ml) and the organic solution was washed with brine (3×50 ml), dried and evaporated. The solid residue was purified by crystallization.
1 H NMR (CDCl 3 ) δ 0. General procedure for the synthesis of 6-arylmethyl-3,4-dihydro-5-iodo-2-(1-methylpropylthio)pyrimidin-4(3H)-ones (5a′,d′). For example, 3,4-Dihydro-5-iodo-2-(1-methylpropylthio)-6-(1-naphthylmethyl)pyrimidin-4(3H)-one (5d′) N-Chlorosuccinimide (0.2 g, 1.3 mmol) in acetone (5 ml) and NaI (0.2 g, 1.3 mmol) in the same solvent (5 ml) were combined, stirred for 10 min, filtered and evaporated under reduced pressure. The resulting N-iodosuccinimide (1.3 mmol) was dissolved in dry chloroform (10 ml) and treated with 3,4-dihydro-2-(1-methylpropylthio)-6-(1-naphthylmethyl)pyrimidin-4(3H)-one (10a, Mai et al., 1997) (0.4 g, 1.2 mmol). The mixture was heated at 70°C for 1 h; after cooling, the solvent was evaporated, water (100 ml) was added to the residue and the aqueous layer was extracted with ethyl acetate (3×50 ml). The organic extracts were collected, washed with brine (3×50 ml), dried and evaporated to furnish crude 5d′, which was purified by crystallization.
1 H NMR (DMSO-d 6 ) δ 0. General procedure for the synthesis of 6-arylmethyl-5-bromo-3,4-dihydro-2-(1-methylpropylthio)pyrimidin-4(3H)-ones (5b′,e′). For example, 5-Bromo-3,4-dihydro-2-(1-methylpropylthio)-6-(phenylmethyl)pyrimidin-4(3H)-one (5b′)
Benzoyl peroxide (10 mg) was added to a mixture of 3,4-dihydro-2-(1-methylpropylthio)-6-(phenylmethyl)pyrimidin-4(3H)-one (9a, Mai et al., 1995) (0.2 g, 0.7 mmol) and N-bromosuccinimide (0.13 g, 0.7 mmol) in dry carbon tetrachloride (50 ml). The resulting solution was heated at reflux for 2 h. After cooling, the mixture was diluted with water (100 ml), separated and the aqueous layer was extracted with chloroform (3×20 ml). The organic extracts were collected, washed with brine (3×50 ml), dried and evaporated to furnish crude 5b′, which was purified by crystallization. , 4.85; N, 7.93; S, 9.08; Br, 22.62. Found: C, 50.87; H, 4.79; N, 8.02; S, 8.91; Br, 22.74 . †Compound dose required to reduce the viability of mock-infected cells by 50%, as determined by the MTT method. ‡Compound dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity, as determined by the MTT method. §SI: Selectivity index, CC 50 /EC 50 ratio. ¶Higher concentrations could not be achieved because of crystallization of compounds in the culture medium.
5-Chloro-3,4-dihydro-2-(1-methylpropylthio)-6-(phenylmethyl)pyrimidin-4(3H)-one (5c′)
A mixture of 3,4-dihydro-2-(1-methylpropylthio)-6-(phenylmethyl)pyrimidin-4(3H)-one (9a) (0.2 g, 0.7 mmol) and N-chlorosuccinimide (0.16 g, 1.2 mmol) in dry chloroform (10 ml) was heated at reflux for 3 h. After cooling, the mixture was diluted with water (100 ml), separated and the aqueous layer was extracted with chloroform (3×20 ml). The organic extracts were collected, washed with brine (3×50 ml), dried and evaporated to furnish crude 5c′, which was purified by crystallization. C, 58.34; H, 5.55; N, 9.07; S, 10.38; Cl, 11.48. Found: C, 58.55; H, 5.72; N, 9.01; S, 10.46; Cl, 11.34. General procedure for the synthesis of 5-aminomethyl-6-arylmehtyl-3,4-dihydro-2-(1-methylpropylthio)pyrimidin-4(3H)-one derivatives (5f′-I′). For example, 3,4-Dihydro-5-(N,N-dimethylaminomethyl)-2-(1-methylpropylthio)-6-(phenylmethyl)pyrimidin-4(3H)-one (5f′)
A mixture of 3,4-dihydro-2-(1-methylpropylthio)-6-(phenylmethyl)pyrimidin-4(3H)-one (9a) (1.0 g, 3.6 mmol), paraformaldehyde (0.26 g, 8.7 mmol), dimethylamine hydrochloride (0.7 g, 8.7 mmol) and glacial acetic acid (0.05 ml) in absolute ethanol (10 ml) was heated at reflux for 18 h. After cooling, the reaction was quenched with 5% sodium carbonate solution (50 ml) and extracted with ethyl acetate (3×50 ml). The organic extracts were collected, washed with brine (50 ml), dried and evaporated to give a residue (5f′), which was purified by passing through a silica gel column eluting with ethyl acetate.
1 H NMR (CDCl 3 ) δ 0. H, 7.60; N, 12.68; S, 9.67. Found: C, 65.21; H, 7.55; N, 12.73; S, 9.62. 3,4-Dihydro-2-(1-methylpropylthio)-4-oxo-6-(phenylmethyl)pyrimidin-5-carboxylic acid (5j′) A 0.97 M solution of n-butyl lithium in n-hexane (4.4 ml, 4.2 mmol) was added dropwise to a stirred solution of 5-bromopyrimidin-4(3H)-one derivative 5b′ (0.7 g, 1.9 mmol) in dry diethyl ether (100 ml) under nitrogen atmosphere at -70°C. The resulting mixture was stirred for 30 min more, and then poured into diethyl ether (100 ml) saturated with dry ice. The reaction mixture was allowed to reach room temperature, then treated with water (200 ml). The aqueous layer was separated, acidified with 10% HCl, and extracted with ethyl acetate (3×50 ml). The extracts were washed with brine (100 ml), dried and concentrated to give a residue, which was purified by column chromatography on silica gel (eluent: ethyl acetate) followed by crystallization. C, 60.36; H, 5.70; N, 8.80; S, 10.07. Found: C, 60.45; H, 5.72; N, 8.89; S, 9.89. Ethyl 3,4-Dihydro-2-(1-methylpropylthio)-4-oxo-6-(phenylmethyl)pyrimidin-5-carboxylate (5k′) 96% Sulphuric acid (0.04 ml, 0.8 mmol) was added to a solution of 3,4-dihydro-2-(1-methylpropylthio)-4-oxo-6-(phenylmethyl)pyrimidin-5-carboxylic acid 5j′ (1.26 g, 4.0 mmol) in absolute ethanol (50 ml), and the mixture was heated at reflux overnight. After cooling, the solvent was concentrated under reduced pressure, the residue was partitioned between water (100 ml) and diethyl ether (100 ml) and phases were separated. The aqueous layer was extracted with diethyl ether (2×50 ml), the collected organic extracts (200 ml) were washed with sodium hydrogen carbonate saturated solution (100 ml) and brine (100 ml), dried and evaporated to furnish a residue (5k′), which was purified by column chromatography on silica gel (eluent: ethyl acetate/chloroform 1/1) followed by crystallization. 
Materials and Methods: Virology

Compounds
Compounds were solubilized in DMSO at 200 µM and then diluted in culture medium.
Cells and viruses
MT-4, C8166, H9/III B and CEM cells were grown at 37°C in a 5% CO 2 atmosphere in RPMI 1640 medium, supplemented with 10% fetal calf serum (FCS), 100 IU/ml penicillin G and 100 µg/ml streptomycin. Cell cultures were checked periodically for the absence of mycoplasma contamination with a MycoTect Kit (Gibco). Human immunodeficiency viruses type-1 (HIV-1, III B strain) and type-2 (HIV-2 ROD strain, kindly provided by Dr L Montagnier, Paris, France) were obtained from supernatants of persistently infected H9/III B and CEM cells, respectively. HIV-1 and HIV-2 stock solutions had titres of 4.5×10 6 and 1.4×10 5 50% cell culture infectious dose (CCID 50 )/ml, respectively.
HIV titration
Titration of HIV was performed in C8166 cells by the standard limiting dilution method (dilution 1:2, four replica wells per dilution) in 96-well plates. The infectious virus titre was determined by light microscope scoring of cytopathicity after 4 days of incubation, and the virus titres were expressed as CCID 50 /ml.
Anti-HIV assays
Activity of the compounds against HIV-1 and HIV-2 multiplication in acutely infected cells was based on the inhibition of virus-induced cytopathicity in MT-4 and C8166 cells, respectively. In brief, 50 µl of culture medium containing 1×10 4 cells were added to each well of flat-bottom microtiter trays containing 50 µl of culture medium with or without various concentrations of the test compounds. Then 20 µl of an HIV suspension containing 100 (HIV-1) or 1000 (HIV-2) CCID 50 (50% cell culture infective dose) were added. After a 4-day incubation (5 days for HIV-2) at 37°C, the number of viable cells was determined by the 3-(4,5-dimethylthiazol-1-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) . Cytotoxicity of the compounds was evaluated in parallel with their antiviral activity. It was based on the viability of mockinfected cells, as monitored by the MTT method.
Results
Chemistry
The majority of ethyl aryl(or heteroaryl)acetylacetates 7, key intermediates for the synthesis of DABO derivatives 5a-h,k-z and 6a-w, were prepared by the general procedure A (Figure 2 ), according to the previously reported simple and high-yield method , which Table 4 . Cytotoxicity and anti-HIV-1 activity of new DABO derivatives 6*
Discussion
Recently reported molecular modelling studies of S-DABO, DATNO and F 2 -S-DABO derivatives have shown the presence of a favourable effect of 2,6-difluorination related to an attractive π-stacking interaction taking place between the benzene ring of the ligand (made electron-deficient by the two fluorines) and the electron-rich benzene ring of Tyr188 located in the non-nucleoside binding cleft of the RT. As a matter of fact, among the new C-5 substituted DABO derivatives, the highest anti-HIV-1 potency is shown by compounds belonging to the F 2 -S-DABO series. This confirms the importance of the 2,6-difluorophenylmethyl moiety as a C-6 substituent. As observed for other DABO series, the potency of F 2 -S-DABOs is inversely related to the size of the C-5 alkyl substituent, with a trend dissimilar to that observed with the related HEPT derivatives, in which the smaller is the substituent at C-5, the lower is the potency of compounds (Tanaka et al., 1992; Sbardella et al., 2000) .
Interestingly, F 2 -S-DABOs inhibit the Y181C mutant virus in the low micromolar range. Studies are in progress to find proper substituents to be introduced in the F 2 -S-DABO skeleton in order to increase the DABOs anti-HIV activity against clinically relevant HIV-1 mutants.
With the sole exception of small alkyl groups, introduction of substituents (such as halogen atoms, carboxy and carbethoxy, N,N-dimethylamino-, piperidino-, and Nmethyl piperazinomethyl groups) at the C-5 position of the pyrimidine ring yielded considerably less potent (5a′-d′,k′) or inactive (5e′-j′) compounds.
Concerning new C-6 substituted compounds, it is remarkable that a severe decrease of antiviral activity was obtained following both the introduction of an electronwithdrawing group (trifluoromethyl) in the phenylmethyl moiety of the S-DABO skeleton and the replacement of the phenyl ring with the electron-deficient pyridyl ring.
The above results suggest that, in addition to electronic effect, other chemico-physical parameters (steric and lipophylic) play a role in the interaction of DABOs with the HIV-1 RT non-nucleoside binding site.
